These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 9046988

  • 1. Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance.
    Sumiyoshi T, Hasegawa M, Jayathilake K, Meltzer HY.
    Biol Psychiatry; 1997 Mar 01; 41(5):560-6. PubMed ID: 9046988
    [Abstract] [Full Text] [Related]

  • 2. Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response.
    Koreen AR, Lieberman J, Alvir J, Mayerhoff D, Loebel A, Chakos M, Amin F, Cooper T.
    Arch Gen Psychiatry; 1994 Feb 01; 51(2):132-8. PubMed ID: 7905259
    [Abstract] [Full Text] [Related]

  • 3. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.
    Baeza I, Castro-Fornieles J, Deulofeu R, de la Serna E, Goti J, Salvà J, Bernardo M.
    Psychiatry Res; 2009 Jul 30; 168(2):110-8. PubMed ID: 19501918
    [Abstract] [Full Text] [Related]

  • 4. Increments in plasma homovanillic acid concentrations after neuroleptic discontinuation are associated with worsening of schizophrenic symptoms.
    Khan RS, Amin F, Powchik P, Knott P, Goldstein M, Apter S, Kerman B, Jaff S, Davidson M.
    Prog Neuropsychopharmacol Biol Psychiatry; 1990 Jul 30; 14(6):879-84. PubMed ID: 1980541
    [Abstract] [Full Text] [Related]

  • 5. Plasma HVA in psychiatric patients: longitudinal studies.
    Javaid JI, Sharma RP, Janicak PG, Davis JM.
    Psychopharmacol Bull; 1990 Jul 30; 26(3):361-5. PubMed ID: 2274637
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine.
    Sumiyoshi T, Hasegawa M, Jayathilake K, Meltzer HY.
    Psychiatry Res; 1997 Mar 24; 69(2-3):113-21. PubMed ID: 9109179
    [Abstract] [Full Text] [Related]

  • 11. Haloperidol response and plasma catecholamines and their metabolites.
    Green AI, Alam MY, Boshes RA, Waternaux C, Pappalardo KM, Fitzgibbon ME, Tsuang MT, Schildkraut JJ.
    Schizophr Res; 1993 Jun 24; 10(1):33-7. PubMed ID: 8369230
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.
    Suzuki E, Kanba S, Koshikawa H, Nibuya M, Yagi G, Asai M.
    J Psychiatry Neurosci; 1996 May 24; 21(3):167-71. PubMed ID: 8935328
    [Abstract] [Full Text] [Related]

  • 14. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients.
    Szymanski S, Lieberman JA, Alvir JM, Mayerhoff D, Loebel A, Geisler S, Chakos M, Koreen A, Jody D, Kane J.
    Am J Psychiatry; 1995 May 24; 152(5):698-703. PubMed ID: 7726309
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Relationship between plasma homovanillic acid and outcome in patients with psychosis spectrum disorders.
    van de Kerkhof NW, Fekkes D, van der Heijden FM, Egger JI, Verhoeven WM.
    Neuropsychobiology; 2015 May 24; 71(4):212-7. PubMed ID: 26279280
    [Abstract] [Full Text] [Related]

  • 17. Plasma homovanillic acid in schizophrenics: supportive evidence for the two-subtype hypothesis.
    Chen TY, Lee CF, Lung FW, Lee TC, Lin WL, Hu WH, Yeh EK, Chang WH.
    Taiwan Yi Xue Hui Za Zhi; 1989 Jun 24; 88(6):584-8. PubMed ID: 2571672
    [Abstract] [Full Text] [Related]

  • 18. Plasma homovanillic acid, plasma anti-D1 and -D2 dopamine-receptor activity, and negative symptoms in chronically mediated schizophrenia.
    Suzuki E, Kanba S, Nibuya M, Koshikawa H, Nakaki T, Yagi G.
    Biol Psychiatry; 1992 Feb 15; 31(4):357-64. PubMed ID: 1348430
    [Abstract] [Full Text] [Related]

  • 19. Variability of plasma homovanillic acid over 13 months in patients with schizophrenia; relationship with the clinical response and the Wisconsin card sort test.
    Zumárraga M, González-Torres MA, Arrue A, Dávila R, Dávila W, Inchausti L, Pérez-Cabeza L, Fernández-Rivas A, Bustamante S, Basterreche N, Guimón J.
    Neurochem Res; 2011 Aug 15; 36(8):1336-43. PubMed ID: 21475956
    [Abstract] [Full Text] [Related]

  • 20. Correlation between plasma homovanillic acid levels and the response to atypical antipsychotics in male patients with schizophrenia.
    Kaneda Y, Kawamura I, Ohmori T.
    Clin Neuropharmacol; 2005 Aug 15; 28(6):262-4. PubMed ID: 16340379
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.